NCT07147361View on ClinicalTrials.gov

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

800

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Esophageal Squamous Cell Carcinoma (ESCC)Cervical Squamous Cell CarcinomaLung Squamous Cell CarcinomaHead and Neck Squamous Carcinoma
Trial Locations (1)

100021

Department of Etiology and Carcinogenesis, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER